Quartett C-C031/P-C031 | CD31 (QR034)

品名：IDH1 R132H (QM002) | Monoclonal mouse antibody

货号：C-I001/P-I001

品牌：Quartett

规格：0.1 ml; 0.5 ml; 1 ml; 3 ml; 7 ml; 15 ml

产品描述

Isocitrate dehydrogenase 1/IDH1 is an enzyme that catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate to form alpha-ketoglutarate and CO2 in a two-step reaction. The IDH1 protein is localized in the cytoplasm and peroxisomes. It is expressed in a wide variety of species, including organisms lacking a complete citric acid cycle. Gliomas are the most common primary CNS malignancy. The two most common types of gliomas are astrocytomas and oligodendrogliomas. Three pathways of glioma development have been identified: primary glioblastomas, which arise de novo without lower-grade precursors; astrocytomas that begin as grade II or III and then transform into secondary glioblastomas; and oligodendrogliomas, which can transform into anaplastic oligodendrogliomas. The IDH1 R132H point mutation is detected in more than 70% of gliomas, frequently in WHO grade II and III gliomas and secondary grade IV glioblastomas. The antibody QM002 is highly specific for the R132H point mutation and allows the diagnosis of astrocytomas or oligodendrogliomas. The high rate of IDH1 mutations in oligodendroglial tumors makes this mutation particularly useful for distinguishing oligodendrogliomas from other tumors with a clear cell appearance. IDH1 mutations have been shown to predominantly inhibit the catalytic activity of IDH1. Assessment of IDH1 status can be achieved by immunohistochemical detection of the mutated protein. In cases with negative or equivocal immunostaining results, further analysis using DNA-based methods is required. Investigation of IDH1 status is important for diagnostic and prognostic considerations in primary brain tumors. Mutated tumors generally have a better prognosis.